ZWZhi-Qi Wang

Zhi-Qi Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhi-Qi Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineering Natural Product Nanomedicines to Modulate Tumor Immunometabolism for Enhanced Cancer Immunotherapy

    by Yang Xiao, Shaowen Lan, Yuping Dai, Xuenan Liu, Chaowen Huang, Changming Yang, Zhiqi Wang, Linghui Zou

    Tumor metabolic reprogramming contributes to an immunosuppressive microenvironment and limits the efficacy of cancer immunotherapy. Natural products can regulate multiple metabolic pathways, but their therapeutic application is often restricted by poor bioavailability and insufficient tumor exposure. Nanomedicine offers a means to overcome these limitations while enabling more selective metabolic intervention. This review examines how natural product nanomedicines remodel tumor immunometabolism and influence antitumor immunity. Current evidence shows that these nanomedicines can regulate glucose and lactate metabolism, lipid and amino acid-associated metabolism, and mitochondrial/redox homeostasis. Such metabolic remodeling has been associated with improved CD8+ T-cell activity, altered immunosuppressive immune populations, induction of immunogenic cell death, and improved responses to immune checkpoint blockade in selected studies. However, causal links between metabolic regulation and immune remodeling remain insufficiently defined, and metabolic interventions may exert distinct effects across tumor and immune cell populations. Future studies should emphasize cell-specific targeting, direct assessment of metabolic target engagement, and pharmacokinetic-pharmacodynamic relationships. Natural product nanomedicines therefore represent a promising platform for integrating metabolic intervention with cancer immunotherapy.

  • Open Access

    Salvianolic Acid B Attenuates Liver Fibrosis via Suppression of Glycolysis-Dependent m1 Macrophage Polarization

    by Hao Song, Ze-Wei Li, Wei Xu, Yang Tan, Ming Kuang, Gang Pei, Zhi-Qi Wang

    Liver fibrosis, a critical pathological feature of chronic liver injury, is closely associated with macrophage-mediated inflammatory responses and metabolic reprogramming. Blocking the fibrosis process will be beneficial to the treatment and recovery of the disease. Liver macrophages are a remarkably heterogeneous population of immune cells that play multiple functions in homeostasis and are central to liver fibrosis. Glycolysis-mediated macrophage metabolic reprogramming leads to an increase in the proportion of M1 macrophages and the release of pro-inflammatory cytokines. The present study aimed to investigate the therapeutic effect and mechanism of acid B (SAL B) against carbon tetrachloride (CCl4)-induced liver fibrosis. Here, we demonstrate that SAL B reduced the production of inflammatory factors in CCl4-induced liver fibrosis. Mechanistically, SAL B increased the expression of migration inhibitor 1 (MIG1) by inhibiting DNMT1-mediated methylation of the MIG1 promoter. Subsequently, MIG1 reduced the transcription of lactate dehydrogenase A (LDHA) and hexokinase 2 (HK2) which blocked glycolysis-mediated macrophage M1 polarization. In summary, our results suggested that SAL B is a promising intervention for ameliorating liver fibrosis.